The abstract is read at the publisher; the summary is JClub's.
In adults with primary aldosteronism newly starting spironolactone or eplerenone, cardiovascular risk over 3.0 years was lowest when achieved potassium was 4.5–<5.0 mmol/L (aHR 0.65 vs <4.0).
- Why it matters: Serum potassium is routinely checked after mineralocorticoid receptor antagonist therapy, but the long-term prognostic value of the early potassium level—and whether “correction” targets matter—was unclear.
- What they did: Using a 180-day landmark design in TriNetX (n=4,169), achieved potassium on days 14–180 was grouped (<4.0, 4.0–<4.5, 4.5–<5.0, ≥5.0 mmol/L) and analyzed with cause-specific Cox and Fine-Gray models for outcomes.
- The result: Over a median 3.0 years, 623 composite events occurred, with risk lowest at 4.5–<5.0 mmol/L and a larger potassium rise linked to lower risk; incident heart failure showed a similar pattern (248 events).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.